Royalty Pharma plc Contracts & Agreements

Third Supplemental Indenture, dated as of June 10, 2024, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee (Filed With SEC on June 10, 2024)

Underwriting Agreement, dated as of June 3, 2024, by and among Royalty Pharma plc, Royalty Pharma Holdings Ltd, RP Management, LLC and the underwriters named therein (Filed With SEC on June 4, 2024)

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 15, 2024)

Amended and Restated Revolving Credit Agreement, dated as of September 15, 2021, as amended by Amendment No. 1, dated as of October 31, 2022, as amended by Amendment No. 2, dated... (Filed With SEC on December 27, 2023)

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 15, 2023)

Second Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on November 8, 2022)

Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Holdings Limited and RP Management, LLC (Filed With SEC on November 8, 2022)

Amended and Restated Management and Services Agreement dated October 3, 2022, among the Company and RP Management, LLC (Filed With SEC on November 8, 2022)

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 15, 2022)

Second Supplemental Indenture, dated as of July 26, 2021, Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee (Filed With SEC on July 26, 2021)

Underwriting Agreement, dated as of July 15, 2021 by and among Royalty Pharma plc, Royalty Pharma Holdings Limited, RP Management, LLC and the underwriters named therein (Filed With SEC on July 16, 2021)

Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 24, 2021)

Amendment No. 2 to the Amended and Restated Purchase and Sale Agreement, dated October 30, 2020, by and among RPI Finance Trust, RPI 2019 Intermediate Finance Trust and Cystic... (Filed With SEC on November 5, 2020)

Form of Deed of Indemnity (Filed With SEC on October 13, 2020)

Registration Rights Agreement dated June 18, 2020, among the Company and the Persons listed on Schedule A and Schedule B thereto (Filed With SEC on October 13, 2020)

Director Appointment Agreement, dated June 9, 2020, between the Company and Mr. Germano Giuliani (Filed With SEC on October 13, 2020)

Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated (Filed With SEC on October 13, 2020)

Amendment No. 1 to the Amended and Restated Purchase and Sale Agreement, dated October 13, 2016 with the Cystic Fibrosis Foundation (Filed With SEC on October 13, 2020)

Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as... (Filed With SEC on October 13, 2020)

Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)

Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)

Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)

Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis... (Filed With SEC on October 13, 2020)

Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on October 13, 2020)

Form of Independent Director Equity Incentive Plan (Filed With SEC on October 13, 2020)

Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee (Filed With SEC on October 13, 2020)

First Supplemental Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee (Filed With SEC on October 13, 2020)

Registration Rights Agreement, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, BofA Securities, Inc., Citigroup Global Markets Inc., Goldman... (Filed With SEC on October 13, 2020)

Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Ltd, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners... (Filed With SEC on October 13, 2020)

Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC (Filed With SEC on October 13, 2020)

Form of Class A Ordinary Share Certificate (Filed With SEC on October 13, 2020)

Form of Underwriting Agreement (Filed With SEC on October 13, 2020)

Registration Rights Agreement, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd., BofA Securities, Inc., Citigroup Global Markets Inc., Goldman... (Filed With SEC on September 2, 2020)

First Supplemental Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee (Filed With SEC on September 2, 2020)

Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee (Filed With SEC on September 2, 2020)

Registration Rights Agreement dated June 18, 2020, among the Company and the Persons listed on Schedule A and Schedule B thereto (Filed With SEC on June 19, 2020)

Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on June 19, 2020)

Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC (Filed With SEC on June 19, 2020)

Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International... (Filed With SEC on June 19, 2020)

Form of Class A Ordinary Share Certificate (Filed With SEC on June 11, 2020)

Director Appointment Agreement, dated June 9, 2020, between the Company and Mr. Germano Giuliani (Filed With SEC on June 11, 2020)

Form of Independent Director Equity Incentive Plan (Filed With SEC on June 11, 2020)

Form of Underwriting Agreement (Filed With SEC on June 8, 2020)

Amendment No. 1 to the Amended and Restated Purchase and Sale Agreement, dated October 13, 2016 with the Cystic Fibrosis Foundation (Filed With SEC on June 2, 2020)

Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated (Filed With SEC on June 2, 2020)

Form of Deed of Indemnity (Filed With SEC on June 2, 2020)

Form of Registration Rights Agreement (Filed With SEC on June 2, 2020)

Form of Exchange Agreement (Filed With SEC on June 2, 2020)

Form of Management and Services Agreement, dated , 2020, among Royalty Pharma plc and RP Management, LLC (Filed With SEC on May 22, 2020)

Form of Amended and Restated Management and Services Agreement, dated, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on May 22, 2020)

Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis... (Filed With SEC on May 22, 2020)

Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)

Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)

Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)

Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as... (Filed With SEC on May 22, 2020)

Credit Agreement, dated February 11, 2020, between RPI 2019 Intermediate Finance Trust, as borrower, Bank of America, N.A., as administrative agent, and certain lender parties... (Filed With SEC on May 22, 2020)

Category

Industry

Companies

Contracts

Royalty Pharma plc Contracts & Agreements